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Abstract
Background: Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common conditions that affect over 5 million
people in the United Kingdom. These groups of patients suffer significantly from breathlessness and recurrent exacerbations that
can be difficult to diagnose and go untreated. A common feature of COPD and asthma is airway inflammation that increases
before and during exacerbations. Current methods of assessing airway inflammation can be invasive, difficult to perform, and
are often inaccurate. In contrast, measurement of exhaled breath condensate (EBC) hydrogen peroxide (H2O2) is performed during
normal tidal breathing and is known to reflect the level of global inflammation in the airways. There is a need for novel tools to
diagnose asthma and COPD earlier and to detect increased airway inflammation that precedes an exacerbation.
Objective: The aim of this study was to explore the use of a new handheld device (called Inflammacheck) in measuring H2O2
levels in EBC. We will study whether it can measure EBC H2O2 levels consistently and whether it can be used to differentiate
asthma and COPD from healthy controls.
Methods: We will perform a cross-sectional, feasibility, pilot study of EBC H2O2 levels, as measured by Inflammacheck, and
other markers of disease severity and symptom control in patients with asthma and COPD and volunteers with no history of lung
disease. Participants will be asked to provide an exhaled breath sample for measurement of their EBC H2O2 using Inflammacheck.
The result will be correlated with disease stage, spirometry, fractional exhaled nitric oxide (FeNO), and symptom control scores.
Results: This study’s recruitment is ongoing; it is anticipated that the results will be available in 2018.
Conclusions: The EXhaled Hydrogen peroxide As a marker of Lung diseasE (EXHALE) pilot study will provide an evaluation
of a new method of measuring EBC H2O2. It will assess the device’s consistency and ability to distinguish airway inflammation
in asthma and COPD compared with healthy controls.
(JMIR Res Protoc 2018;7(1):e25)   doi:10.2196/resprot.8768
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Introduction
Burden of Chronic Obstructive Pulmonary Disease
and Asthma
Chronic Obstructive Pulmonary Disease (COPD) is a common
and treatable condition that is characterized by predominately
irreversible and progressive airflow limitation. COPD is a
leading cause of morbidity and mortality worldwide, and its
prevalence is predicted to increase substantially in the coming
decade [1]. In the United Kingdom alone, COPD affects an
estimated 3 million people, with two-thirds remaining
undiagnosed [2,3]. Delays in reaching an accurate diagnosis
impact on people’s quality of life (QoL) and health care resource
utilization. COPD is associated with a significant economic and
social burden. In 2011, there were over a million in-patient bed
days caused by acute exacerbations of COPD, with a severe
exacerbation requiring admission to hospital costing up to
£1600, therefore having a major impact on health care
expenditure [4]. COPD also has a personal burden, causing 24
million lost working days annually, costing the UK economy
£3.8 billion [5,6].
Asthma is estimated to affect over 3.5 million people in the
United Kingdom, with 250,000 experiencing severe disease
with frequent exacerbations [7]. Despite increasing numbers of
treatment options, there were still over 900 deaths because of
asthma in 2014 [8]. The economic burden of treating asthma is
huge, costing in excess of £1 billion per year [4,7]. Like COPD,
asthma also has a dramatic personal cost with 1 in 5 asthmatics
in the United Kingdom reporting serious concerns that their
next asthma attack will kill them [9]. Delays in correctly
diagnosing and phenotyping asthma can lead to poor disease
control, high emergency health care use, and inappropriate
treatment [10,11]. There is a need for additional, widely
accessible tools to aid in the accurate diagnosis and phenotyping
of both asthma and COPD.
Rationale for Measuring Airway Inflammation
A common feature of COPD and asthma is chronic airway
inflammation, which worsens during exacerbations. These are
frequently triggered by infections and inhaled irritants resulting
in epithelial injury, neutrophil and eosinophil activation, and
release of inflammatory cytokines [10,12]. This all contributes
to the bronchoconstriction, smooth muscle hypertrophy, and
airflow obstruction that are features of asthma [13]. Where there
is prolonged exposure to toxic irritants in COPD, there is
ongoing airway inflammation that can continue even after
smoking or irritant cessation and begin before the development
of clinical symptoms [1,14].
Airway inflammation in asthma and COPD leads to an
imbalance between the production of reactive oxygen species
(ROS) and the ability of the body to counteract their harmful
effects through neutralization by antioxidants; this is termed as
oxidative stress [15-17]. Increased expression of ROS by
activated inflammatory cells, including neutrophils and
eosinophils, can lead to further generation of inflammatory
mediators, causing damage to epithelial cells and increased
bronchial hyperreactivity [14]. ROS are metabolized in cells to
produce highly reactive oxidants such as hydrogen peroxide
(H2O2), which is fat soluble and can move across cell
membranes. As H2O2 is volatile and readily equilibrates with
air, its presence can be detected in exhaled breath condensate
(EBC). Therefore, measurement of EBC H2O2 gives a
quantitative measure of oxidative stress and airway inflammation
[18-21].
Current Measures of Airway Inflammation
The current gold standard tool for assessing airway
inflammation and oxidative stress is fiberoptic bronchoscopy
with bronchial wall biopsy and bronchial fluid lavage [22,23].
This is an invasive procedure that is not suitable for routine
clinical practice or regular repeat sampling. This is because it
carries a small but important risk, with complications occurring
in up to 4.3% of procedures and a reported procedure-related
mortality of up to 0.1% [24]. In patients with underlying asthma
and COPD, the risk is even greater, with up to 10% of patients
with asthma developing respiratory symptoms post
bronchoscopy [24]. Bronchoscopy is also an expensive tool,
with British Thoracic Society guidelines recommending a
minimum of two qualified nurses present throughout
bronchoscopy procedures and one qualified nurse to recover a
patient post bronchoscopy [24]. Furthermore, sample analysis
requires a series of laboratory measurements, and results can
take over 24 hours to become available, causing delays in
clinical decision making.
Induced sputum analysis is a semi-invasive means of assessing
airway inflammation [25]. However it can be unpleasant,
technically demanding, and time consuming, and as a result, is
not always possible in patients with more severe airflow
obstruction and poor lung function. It is not always well
tolerated by patients and is not suitable for repeat sampling [26].
Noninvasive means of assessing airway inflammation presently
measure fractional exhaled nitric oxide (FeNO—a specific
measure of eosinophilic airway inflammation) [27]. This requires
controlled exhalation for at least 6 seconds, making the test
unsuitable for patients with significantly impaired lung function
and especially those who are tachypnoeic during an
exacerbation. Furthermore, FeNO is lowered in current smokers,
limiting its diagnostic use, and it also does not measure
neutrophilic airway inflammation, a recognized component of
COPD and steroid insensitive asthma. It has been reported that
up to 50% of patients with severe asthma do not have
eosinophilic-driven disease (noneosinophilic) and, as a
consequence, FeNO cannot monitor management in this group
[28].
Exhaled Breath Condensate Hydrogen Peroxide
EBC contains aerosolized particles from the airway epithelial
lining fluid [29], including volatile water-soluble compounds
such as H2O2. Measurement of EBC H2O2 therefore gives a
direct, quantitative measure of airway inflammation [21,30,31].
In contrast to current measures of airway inflammation,
collection of EBC H2O2 is performed during tidal breathing,
making it noninvasive and easy to perform. It can be repeated
quickly and is well tolerated even in patients with severe airways
disease. It is widely appreciated that EBC H2O2 measurement
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has the potential to improve clinical practice by safely providing
vital information on aspects of disease that are currently
inaccessible [32].
To date, measurement of H2O2 in the EBC has required complex,
multi-step processing of the collected breath samples to produce
a result and as a consequence has largely been used as a research
tool [33]. The evidence from these past collection techniques
show that EBC H2O2 levels are significantly higher in COPD
patients compared with healthy controls [34]. It has also been
demonstrated that the levels rise further during COPD
exacerbations, and there is some evidence that EBC H2O2 levels
correlate with COPD disease severity [21]. Within asthma, EBC
H2O2 concentrations were significantly higher in asthmatics
who were nonsmokers compared with healthy subjects [30,35].
The level of EBC H2O2 also correlated with asthma severity
and phenotype, being significantly higher in moderate asthmatics
compared with those with mild asthma and in asthmatics with
neutrophil predominant airway inflammation [36,37].
Furthermore, higher values of EBC H2O2 were observed in
uncontrolled asthma (defined as increased use of short-acting
beta-agonist and continued daily symptoms) compared with
healthy subjects and controlled asthmatics [31].
Exhalation Technology Ltd. has developed a battery operated,
handheld device for point of care measurement of H2O2 level
in exhaled breath—the Inflammacheck device. This test involves
simple, relaxed tidal breathing for up to 1 min (20 breaths) into
a mouthpiece. The device collects at least 60 µL of EBC in a
collection cartridge. A total of 30 µL of the collected EBC is
then pipetted by the clinician onto a separate sensor cartridge
that measures the level of H2O2. If this device can be used in a
routine clinical setting, it may give clinicians an immediate
insight into the inflammatory state of the airways. It also has
the potential to identify inflammatory cell specific inflammation
(neutrophilic) that would guide treatment decision making. This
could aid earlier diagnosis and personalized management plans,
ultimately improving patient care. This simple, noninvasive
technique may also make repeat sampling and longitudinal
monitoring of global airway inflammation a realistic possibility.
We aim to assess whether Inflammacheck can differentiate
asthma and COPD from healthy airways and whether its
measurement of EBC H2O2 correlates with other noninvasive
methods of assessing airway inflammation and disease severity.
Information about the reliability and repeatability of the
Inflammacheck sensor also needs to be collected. We will assess
Inflammacheck in patients with asthma, COPD, and healthy
individuals who do not have respiratory disease.
Aims and Objectives
Coprimary Objectives
The coprimary objectives were as follows:
• To determine whether Inflammacheck can differentiate
asthma and COPD from healthy controls.
• Whether Inflammcheck can detect EBC H2O2 levels
consistently and in a repeatable manner.
Secondary Objectives
The secondary objectives were as follows:
• To describe the relationship between EBC H2O2 and the
following:
• Disease severity (Global Initiative for Asthma [GINA]
stage for asthma [38], Global Initiative for Obstructive
Lung Disease [GOLD] stage for COPD [1])
• Disease control (Asthma Control Questionnaire, ACQ
score [asthma] and COPD Assessment Test, CAT score
[COPD])
• QoL (Asthma Quality of Life Questionnaire, AQLQ
score [asthma])
• Spirometry (forced expiratory volume in 1 second
[FEV1], forced vital capacity [FVC], and ratio), with
reversibility where available
• FeNO (ppb)
• Atopic status (asthmatics only)
• To determine the reliability and consistency of the
Inflammacheck sensor in measuring EBC H2O2 levels with
laboratory reference ranges.
• To determine how frequently patients are unable to perform
spirometry, FeNO, and Inflammacheck, or require further
attempts.
• To describe any adverse events during the test procedures.
• To explore participants’ and health care professionals’
(HCPs’) experience of Inflammacheck, including ease of
use and acceptability of the device.
Exploratory Objectives
To determine whether there is a relationship between EBC H2O2,
as measured by Inflammacheck and FeNO, atopic status (skin
prick testing [SPT] result in asthmatics only), exercise, diet,
medications, and effects of inhaled therapy. EBC H2O2 levels
will also be compared with peripheral white cell counts, serum
biochemistry, and markers of inflammation where available.
Methods
Overview
This is a single visit, cross-sectional, feasibility study of EBC
H2O2 levels, as measured by Inflammacheck, and markers of
disease severity and symptom control in patients with asthma,
COPD, and volunteers with no known lung disease.
Outcome Measures
Respiratory outcomes were as follows:
• EBC H2O2 as measured by the Inflammacheck sensor
• EBC H2O2 as measured by a reference and background
sensor
• FeNO
• FEV1, FVC, and ratio.
• GINA stage in asthma patients, GOLD stage in COPD
patients.
• ACQ and CAT scores
• AQLQ score
Process outcomes were as follows:
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• Number of attempts at each procedure
• Whether patient successfully completed procedure
Safety outcome was as follows:
• Any adverse events reported during any of the study
procedures
Experience outcomes were as follows:
• Participant’s perception of device
• HCP’s perception of device
Environmental and biological outcomes included the following:
• Atopic status (SPT result in asthmatics), diet, exercise, and
medication use.
Study Participants
Three populations of older adolescent and adult patients (all
aged ≥16 years) will be invited to participate:
• Asthma patients (n=30)
• COPD patients (n=30)
• Comparator group (n=30)—Volunteers with no previous
history of lung disease (our healthy volunteers). These
healthy volunteers will be recruited from the hospital staff.
This will be facilitated by the hospital and research
communications teams. HCPs, who have assisted patients
performing Inflammacheck, alongside the standard
respiratory tests of spirometry and FeNO, will be invited
to participate in an experience outcome questionnaire at the
end of the study.
Inclusion and Exclusion Criteria
Inclusion criteria for the participants are provided in Textbox
1.
HCPs inclusion criteria were as follows:
• Assisted a minimum of 5 patients in performing the
collection of EBC H2O2 levels using the Inflammacheck
device during the study.
• Willing and able to give informed consent for participation
in the study.
Exclusion criteria for the participants are provided in Textbox
2.
Textbox 1. Inclusion criteria for study participants.
• Male or Female, aged ≥16 years.
• Any of the following conditions:
• A confirmed, clinician-made diagnosis of asthma with symptoms for ≥3 months supported by evidence of any of the following:
• Airflow variability, with a variability in forced expiratory volume in 1 second (FEV1) or peak expiratory flow of >20% across clinic
visits, with concomitant evidence of airflow obstruction (FEV1/FVC ratio <70% on spirometry recorded at any time);
• Airway reversibility with an improvement in FEV1 by ≥12% or 200 mL after inhalation of 400 μg of salbutamol (or equivalent
bronchodilator) via a metered dose inhaler and spacer or nebulizer, recorded at any time;
• Airway hyper-responsiveness demonstrated by Methacholine challenge testing with a provocative concentration of Methacholine
required to cause a 20% reduction in FEV1 (PC20) of ≤ 16 mg/mL or equivalent test, recorded at any time.
• OR a confirmed, clinician-made diagnosis of Chronic Obstructive Pulmonary Disease (COPD) for ≥3 months supported by spirometric
evidence of fixed airflow limitation (postbronchodilator FEV1 / FVC ratio <0.7) recorded at any time.
• OR no known history of lung disease (defined as no current clinical diagnosis of, or be receiving treatment for, a lung disease).
• Willing and able to give informed consent for participation in the study.
Textbox 2. Exclusion criteria for study participants.
The participant may not enter the study if any of the following apply:
• Existing comorbidities that may prevent them from performing spirometry, fractional exhaled nitric oxide (FeNO), or other study measurements
(at the discretion of the clinical investigator).
• Known other lung, chest wall, neuromuscular, or cardiac disease or abnormality (including end-stage disease or cancer) that would confound
symptom scores and spirometry.
• Has received treatment for an exacerbation of their respiratory disease within the last 2 weeks.
• In the opinion of the clinical investigator, participant could be put at risk of harm by having to perform any of the study procedures.
• Unable to comprehend the study and provide informed consent, for example, insufficient command of English in the absence of someone to
adequately interpret.
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Sampling and Sample Size
The sample size was based on our primary objective of
comparing EBC H2O2 values between each pair of the three
main study groups (asthma patients, COPD patients, and
controls). This is a feasibility pilot study of the use of a new
device. For future, larger trials to be conducted using the device,
information is needed to confirm that the Inflammacheck sensor
is accurate and can consistently measure H2O2 in EBC within
patients. There are no previous trials using this version of the
device that can guide a sample size calculation. As a result, the
sample size is based on the research teams’ experience of
delivering previous trials on novel diagnostic tests.
Study Procedures
Recruitment
Outpatients
Patients attending respiratory outpatient clinics at Queen
Alexandra Hospital in Portsmouth will be will be preidentified
from upcoming clinic lists and sent a participant information
sheet (PIS) and an invitation to participate with their clinic letter.
Patients will have adequate time to read this information, and
there will be a contact telephone number and email address on
the invitation letter so that potential participants are able to
discuss the study with a member of the research team before
their clinic visit. Patients who are already enrolled in other
research trials will be invited and allowed to participate in the
study if they so wish. For the recruitment of mild disease,
patients will be identified from specialist respiratory clinics held
in the community. They will be given a PIS with an invitation
to participate in the study.
Healthy Volunteers
Posters advertising the study will be placed in staff rest rooms,
and an email will be sent to all staff (through the hospital
research communications team) to advertise the study. Potential
volunteers will be asked to call or email the study team to so
that further information (PIS) can be sent via an email and an
appointment arranged to discuss the study further.
HCPs
HCPs and members of the research team within the respiratory
department, who perform all respiratory tests on the participants,
will be asked to participate within the study to answer a
questionnaire on their perceptions of the Inflammacheck device.
Only HCPs who have assisted a minimum of 5 patients in
performing the collection of EBC H2O2 levels using
Inflammacheck will be asked to participate.
Screening and Enrollment
Outpatients
Those expressing an interest in the study will have eligibility
assessed and the opportunity to ask any further questions on
their clinic visit. Informed consent will then be taken.
Healthy Volunteers
An appointment will be made with the research team at a
convenient time to confirm eligibility criteria and take informed
consent.
HCPs
At the end of the study, the research team will approach all
HCPs involved in assisting patients in performing the collection
of EBC H2O2 levels using the Inflammacheck device. If HCPs
who have assisted at least 5 participants in performing the study
breathing tests express an interest in participating, informed
consent will be taken.
Study Assessments
A summary of the study assessments and participant flow is
displayed in Figure 1.
Participant Characteristics
Before other study procedures, characteristics of participants
that are known to have a potential influence on respiratory test
results will be documented. These will include the following:
• Demographics: age, gender, and ethnicity
• Anthropometry: Height and weight (to calculate body mass
index)
• Disease severity: GINA stage (asthma), GOLD stage
(COPD)
• Medications participants are taking
• Factors that may affect EBC H2O2 levels including smoking
status (current or former or never), time of last cigarette
(for current smokers only), number of pack years of
smoking (current and former smokers only), use of
mouthwash that morning, time of last dose of inhaled
medication (asthma and COPD patients only), time of last
caffeinated drink, time of last food intake, and time of last
vigorous exercise
Disease Questionnaires
These will be completed only by patients with asthma and COPD
and forms part of their standard clinical assessment in the
outpatient setting.
Asthma Control Questionnaire
The ACQ is a validated 7-item questionnaire for assessing the
level of asthma control over the preceding 7 days. The
questionnaire includes five symptom scores, the frequency of
rescue bronchodilator use, and a measure of airway calibre
(FEV1% predicted). Responses are given on a 6-point scale, and
the overall score is the mean of the responses (0=totally
controlled, 6=severely uncontrolled). Scores over 1.0 are
considered indicative of poor control [39,40].
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Figure 1. Summary of study procedures and the participant flow. COPD: Chronic Obstructive Pulmonary Disease; QAH: Queen Alexandra Hospital;
PIS: participant information sheet; QoL: quality of life; ACQ: asthma control questionnaire; AQLQ: asthma quality of life questionnaire; CAT: COPD
assessment test; SPT: skin prick test; EBC H2O2: exhaled breath condensate hydrogen peroxide; FeNO: fractional exhaled nitric oxide.
Chronic Obstructive Pulmonary Disease Assessment
Test
The CAT is a validated 8-item unidimensional measure of health
status impairment in COPD. It assists patients and their
physicians in quantifying the impact of COPD on the patient’s
health. Responses are given on a 5-point scale with a maximum
total score of 40. The higher the score, the greater the impact
COPD has on the patient’s health; scores of 0 to 9 are considered
low impact, 10 to 20 medium, 21 to 30 high, and >30 very high
[41].
Asthma Quality of Life Questionnaire
The AQLQ is a validated 32-item questionnaire that measures
the functional problems (physical, emotional, social, and
occupational) that are most troublesome to adults with asthma.
Patients are asked to think about how they have been over the
previous 2 weeks and respond to each of the 32 questions on a
7-point scale (7=not impaired at all, 1=severely impaired). The
overall score is the mean of all 32 responses [42,43].
Skin Prick Testing
Asthma participants will have an SPT performed to determine
their atopic status. If the participant has had an SPT performed
and recorded within the last 3 years, then this result will be used.
An SPT is a simple and safe method of testing a person to
determine whether or not they have an IgE-mediated allergic
response to common inhaled allergens [44]. SPT’s will be
performed by trained and experienced respiratory HCPs, who
are also trained in resuscitation techniques. Five common
aero-allergens will be tested for: grass, house dust mite,
aspergillus, cat dander, and dog dander. Atopic status will be
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demonstrated by a positive SPT (wheal diameter ≥3 mm larger
than the negative control).
Respiratory Tests
The participants will then continue with the standard respiratory
assessment element of their clinic visit, with the addition of the
EBC H2O2 levels measurement performed by the Inflammacheck
device, in the order described below. For every test, the
following will be recorded:
• the time the test starts and finishes
• the room temperature at the time of the test
• the time of the participants last inhaled medication dose
• the time of the participants last cigarette (if applicable)
• the time of the participants last food and drink intake
• the time of the participants last vigorous exercise
• whether the test was not possible to complete, and the
reason for this
• if test was performed, the number of attempts required to
complete the test successfully
• any adverse events related to the test that are reported by
the patient or noted by clinical staff during the test
procedures
Exhaled Breath Condensate Hydrogen Peroxide
EBC H2O2 will be measured using the Inflammacheck device
(Exhalation Technology Ltd., Dereham, Norfolk) as specified
by the manufacturer’s instructions. For the participant, this
involves simple relaxed tidal breathing for 20 breaths into a
disposable mouthpiece. Once they have completed this, the
research nurse will remove the collection cartridge, which should
contain at least 60 µL of EBC. The nurse will then pipette 30
µL onto the Inflammacheck sensor cartridge. The sensor
cartridge will be placed back into the device and will give a
reading of EBC H2O2 to the researcher via an attached laptop.
The remaining 30 µL will then be pipetted onto a separate
reference sensor. This reference sensor will give a separate
reading of EBC H2O2, and will be used to confirm the
consistency and reliability of the Inflammacheck sensor. The
results of this test will not be disclosed to the patient to avoid
bias in effort for subsequent tests. The result will also not be
recorded in the clinical notes that are passed to the consulting
doctor as they are not intended to inform patient management
decisions in this study.
Fractional Exhaled Nitric Oxide
FeNO will be measured using a NIOX MINO device (Aerocrine
AB, Solna, Sweden,) or equivalent device for measuring exhaled
nitric oxide level, as specified by the manufacturer’s instructions
and outlined in the American Thoracic Society (ATS) and
European Respiratory Society (ERS) standards. This includes
collection by controlled exhalation at the recommended
expiratory flow rate of 50 mL/s for greater than 6 seconds [45].
Spirometry
Spirometry will be conducted using a spirometer conforming
to ATS and ERS standards as specified by the manufacturer’s
instructions. Participants will inhale rapidly and completely
from functional residual capacity, then exhale in an initial blast
of exhalation, and then continue exhalation until the end of the
test. FEV1 (L), FVC (L), and FEV1/ FVC ratio will be recorded.
FEV1 and FVC will be documented as both absolute values and
as a percentage of the predicted value [46].
Self-Completed Questionnaires
A brief, self-completed questionnaire will be used to evaluate
participant’s opinions of the Inflammacheck device on a
Likert-type scale. Participants will be asked about ease of use,
comfort during testing, perception, and satisfaction of
Inflammacheck. They will also be asked to compare
Inflammacheck with spirometry and FeNO, stating their
preference and which they found easiest to use. At the end of
the study, a questionnaire will be used to evaluate HCPs
opinions of the different study assessments. Informed consent
will be obtained from each HCP to participate within the study.
Only HCPs who performed the respiratory tests during the trial
on a minimum of 5 patients will be asked to participate. The
questionnaire will include a rating for each of the study
assessments (spirometry, FeNO, and EBC H2O2 as measured
by Inflammacheck) on a Likert-type scale. HCPs will be asked
about “ease of use” of each device, their perceptions of patient
experience, and an open-ended question for any further
suggestions.
Discontinuation of Participants From Study and End of
Study
Participants who are unable to perform EBC H2O2 measurement
with Inflammacheck, spirometry, or FeNO will not be
withdrawn. The reason for failing to perform these tests will be
documented in the case report form (CRF). The end of study is
the date of the last participant completing their study procedures.
Safety Assessment
Adverse Event (AE) Definition
An adverse event is any untoward medical occurrence in a
participant taking part in a clinical trial that does not necessarily
have to have a causal relationship with the device under
investigation. An AE can therefore be any unfavorable or
unintended sign, symptom, or disease temporarily associated
with the use of the device, whether or not this has a causal
relationship with the device under investigation.
Recording and Reporting of AEs
There are not expected to be any AEs associated with the use
of the Inflammacheck device. Only AEs that have a reasonable
possibility of being attributable to the device and any other AE
considered to be of clinical significance by the principal
investigator (PI) as causing harm to the patient will be recorded
in the CRF and reported to the sponsor as per their guidelines.
We will record all AEs that are observed during all respiratory
test procedures as a study outcome. Any AEs that do occur and
are considered by the PI to be related to the device will be
expedited to the sponsor, research ethics committee (REC), and
the device manufacturer within 7 days. Lists of the AEs will be
provided to the sponsor when requested.
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Data Handling and Analysis
Data Collection and Management
Enrollment into the study will be documented in each
participants’ medical notes.
Data collection forms will comprise the following:
• Main CRF, including participant characteristics, SPT results,
and respiratory test results.
• Disease control questionnaire (ACQ-7)
• QoL questionnaires (AQLQ and CAT)
• Self-completed questionnaire for participants
• Self-completed questionnaire for HCPs
A bespoke database with preset validation criteria will be created
for the study. Data will be entered and checked against the
original CRF. Further verification will be done according to
frequency and pattern of errors. All data verification will be
carried out by the research team and then by the sponsor during
their monitoring procedures.
Data Analysis
All participants with an EBC H2O2 result as measured by
Inflammacheck will be analyzed. Subgroup analyses may be
carried out if there are sufficient numbers of patients with
particular characteristics, for example, smokers versus
nonsmokers. Demographics or baseline characteristics of each
of the study groups (COPD, asthma, and control) will be
produced, as well as summaries for all groups combined.
Normally distributed continuous variables will be summarized
by the mean and standard deviation, whereas the median and
interquartile range will be preferred for non-normally distributed
continuous variables. The number and percentage of subjects
in each category will be recorded for categorical variables.
Primary Analysis
To establish our primary objective, the primary analysis will be
a comparison of EBC H2O2 values, as measured by the
Inflammacheck device between each pair of the three main study
groups (COPD, asthma, and control). It is expected that the
EBC H2O2 will have a positively skewed distribution. To allow
for the skewed distribution, one approach would be to analyze
the data on a log transformed scale and to compare between
groups using analysis of variance (ANOVA), with post-hoc
tests performed to compare between pairs of groups. It is
possible that there may be EBC H2O2 measurements below the
lower detection limit, and thus, the previous approach may not
be practical. If there are measurements below the detection limit,
this will be dealt with using nonparametric methods. The
Kruskal-Wallis test will be used to compare between the three
groups, with the Mann Whitney test used to compare between
pairs of groups. When comparing between pairs of groups, a
Bonferroni correction will be applied to allow for multiple
testing.
Secondary Analyses
There will be a comparison of EBC H2O2 values, as measured
by the Inflammacheck sensor and the values measured by the
reference sensor. This will determine whether EBC H2O2 is
being measured consistently and reliably by the Inflammacheck
sensor, giving confidence for its use in future versions of the
Inflammacheck device. The association between the EBC H2O2
measurements and a number of other parameters will also be
examined. Associations will be examined with the following:
• FeNO (both high and low levels)
• Disease severity
• Disease control measures
• Disease QoL measures
• Spirometry measures (FEV1, FVC)
• Atopic status (in asthma participants only)
• Items identified in the pretest checklist
Associations with continuous variables will be examined using
either Pearson or Spearman rank correlation (as appropriate).
Associations with categorical measures will be assessed using
ANOVA (using transformed H2O2 values) or the Kruskal-Wallis
test.
The percentage of attempted tests that failed for each test will
be quantified. The association between patient characteristics
and this outcome will be examined. Assuming patient
characteristics are categorical in nature, the chi-square test or
Fisher exact test will be used to examine associations with this
outcome. The secondary analyses will be performed for all
subjects combined and also for each study group separately.
Procedure for Dealing With Missing and Spurious Data
The analysis will include only measured data values, with
missing values omitted from the analysis. No imputation of
missing data will be performed. The data will be examined for
outlying values. Where possible, these will be retained in the
data analysis and their influence minimized by a data
transformation or a nonparametric approach. If such approaches
are not practical, the analysis of the primary outcome will be
performed twice, with and without the outlying values.
Ethics
Participant Confidentiality
The study staff will ensure that the participants’ anonymity is
maintained. The participants will be identified only by initials
and a participant’s ID number on CRF and any electronic
database. All documents will be stored securely and only
accessible by study staff and authorized personnel. The study
will comply with the Data Protection Act that requires data to
be anonymized as soon as it is practicable to do so.
Other Ethical Considerations
The study will not be initiated before the protocol and all study
relevant material such as the informed consent forms and PISs
have received approval or favorable opinion from the REC and
the respective National Health Service (NHS) research and
development (R&D) departments. Any changes to protocol or
relevant study documents will be approved by the sponsor.
Should an amendment be made that requires REC approval, as
defined by REC as a substantial amendment, the changes will
not be instituted until the amendment has been reviewed and
received approval or favorable opinion from the REC and R&D
departments. A protocol amendment intended to eliminate an
JMIR Res Protoc 2018 | vol. 7 | iss. 1 | e25 | p.8http://www.researchprotocols.org/2018/1/e25/
(page number not for citation purposes)
Neville et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
apparent immediate hazard to participants may be implemented
immediately providing that the REC are notified as soon as
possible and an approval is requested. Minor amendments as
defined by REC as nonsubstantial amendment, may be
implemented immediately; and the REC will be informed. All
participants will have adequate time to consider participation
in the study, as per Good Clinical Practice (GCP) guidelines.
Patients who are already enrolled in other research trials will
be invited and allowed to participate in the study if they so wish.
This was discussed with our patient and public involvement
(PPI) representatives who felt that these patients should also
have the opportunity to participate in the study and should not
be excluded. There is a possibility that the study procedures
reveal potential new, previously unknown disease pathology.
This would be more likely to occur in our healthy controls. If
such a circumstance occurs, then the participant will be told of
the results and immediately referred to the most appropriate
NHS department for further review. With the participant's
consent, a letter will be written to their general practitioner
explaining the findings.
Informed Consent
It is the responsibility of the investigator, or a person designated
by the investigator (if acceptable by local regulations), to obtain
written informed consent from each person participating in this
study after adequate explanation of the aims, methods,
anticipated benefits, and potential hazards of the study using
the PIS. The consent process will be documented in the
participant’s notes.
The process for obtaining participant informed consent will be
in accordance with the REC guidance and GCP and any other
regulatory requirements that might be introduced. The PI or
delegate and the participant or any other legally authorized
representative shall both sign and date the informed consent
form before the person can participate in the study. The
participant will keep the PIS and a copy of the signed and dated
consent form. The original will be retained in the trial master
file. A second copy will be filed in the participant’s medical
notes and a signed and dated note made in the notes of when
the PIS was provided and that informed consent was obtained
for the study.
The decision regarding participation in the study is entirely
voluntary. The investigator or their nominee shall emphasize
to them that consent regarding study participation may be
withdrawn at any time without penalty, or affecting the quality
or quantity of their future medical care, or loss of benefits to
which the participant is otherwise entitled.
Patient and Public Involvement
PPI involvement in this study has been sought from patients
with first-hand experience of living with chronic respiratory
disease. Through face-to-face meetings, email, and telephone
contact, we have discussed the concept, impact, and details of
the study with our asthma patient representatives from the
Wessex Asthma Network and our COPD patient representatives
from local British Lung Foundation groups. These people have
lived with severe asthma and COPD and been involved in
previous research studies. They contributed to developing the
key questions and setting our study objectives, ensuring that we
answer the questions that are relevant to people suffering from
airways disease. They have also helped us with patient
recruitment design and the implementation of the
Inflammacheck test within a standard clinical visit so as to
minimize delays for patients who agree to participate in the
study. They have helped design the questionnaire that will be
used to record the participant experience of the device, PIS and
have coauthored the lay summary.
Results
Recruitment to the EXHALE pilot study is ongoing. It is
anticipated that results will be available by early 2018.
Discussion
The EXHALE pilot study will provide an evaluation of a new
method of measuring EBC H2O2. It will assess the device’s
(Inflammacheck) consistency and accuracy of measurement of
EBC H2O2 and its ability to distinguish airway inflammation
in asthma and COPD compared with healthy controls. The data
collected will allow us to develop the device further in response
to participant feedback and prepare for future longitudinal
studies that will assess its capability for detecting asthma and
COPD exacerbations.
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